Published : 22 Nov 2022
Aagami are glad to announce that their Japanese client has given a new assignment, to seek partnerships for one more asset in their pipeline. Aagami also received contract extension for the ongoing assignment.
This is yet another example of continued client satisfaction and trust on Aagami.
The Japanese client is focused on addressing unmet needs and bringing innovative transdermal drugs with their proprietary drug platform formulations and microneedle array technologies. The client does not intend to commercialize the assets themselves in the US and other outside-Japan geographies. Their strategy is to out-license the assets to a company with strong sales presence in the geographies of interest such as the US.
In the new assignment, Aagami are Seeking Licensing/Co-development for client’s Phase 2 (USA) stage Tizanidine patch using proprietary ILTS technology for management of spasticity.
The product is designed to fully deliver the intrinsic potential of tizanidine (bypassing pre-systemic metabolism / avoiding frequent administration). The drug also features reduced side-effect and increased efficacy. Please contact us to receive and evaluate a non-confidential deck.